权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Revealing masked specificities of human Nuclear Receptors

揭示人类核受体的隐藏特性

基本信息

批准号：
9356561
负责人：
ASEEM Z ANSARI
金额：
$ 34.39万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-22 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9356561
关键词：
Adrenal Cortex Hormones Asthma Autoimmune Diseases Base Pairing Binding Binding Sites Biochemical Biological Biological Assay Biological Process Biophysics Cardiovascular system Cataract Cell Extracts Cell Fate Control Cell physiology Cells Characteristics Chromatin Complex Computer Analysis Computing Methodologies Consensus DNA DNA Binding DNA Sequence DNA receptor DNA sequencing Data Data Set Development Diabetes Mellitus Disease Drug Design Drug Targeting Engineering Family Future Gene Expression Gene Targeting Genes Genome Genomics Glaucoma Glucocorticoid Receptor Glucose Goals High-Throughput Nucleotide Sequencing Homeostasis Hormonal Human Hypersensitivity In Vitro Individual Inflammation Insulin Length Ligands Link Liver Lung diseases Malignant Neoplasms Masks Metabolism Methods Mutation Non-Insulin-Dependent Diabetes Mellitus Nuclear Receptor Gene Nuclear Receptors Obesity Outcome Pattern Pharmaceutical Preparations Pharmacologic Substance Physiological Physiology Play Production Proteins RNA Regulator Genes Resistance Retinal Diseases Role Site Solid Neoplasm Specificity TP53 gene Testing Therapeutic Therapeutic Agents Therapeutic Intervention Ursidae Family Validation carcinogenesis cell type cellular development developmental disease drug development experimental analysis functional outcomes genome-wide improved in vivo innovation monomer nervous system disorder new therapeutic target novel novel strategies portability precision medicine preference response small molecule synthetic drug targeted treatment therapy outcome tool transcription factor

项目摘要

PROJECT SUMMARY/ABSTRACT Human Nuclear Receptor (NR) family play significant roles in critical cellular functions such as development, metabolism, and physiology. Disruptions in their DNA binding specificities, due to either mutation in the NR or in the associated DNA regulatory sites, have been implicated in has been implicated in several diseases including glaucoma, cataract, retinal diseases, asthma, inflammation, autoimmune and developmental disorders, hormonal imbalances, obesity, cancers and diabetes. Human NRs are some of the most effective drug targets and the focus of multi-billion dollar pharmaceuticals. A comprehensive understanding of NR gene targeting in vivo, especially when bound to different physiological ligands as well as widely prescribed drugs that have different impact in different individuals and different cell types, will result in a highly informed approach to drug development and deployment. State-of-the-art methods are inadequate to fully characterize the DNA cognate sites of NRs because they often bind as cooperative homotypic or heterotypic oligomers with other TFs. Additionally, the site preferences of NRs are modulated in non-obvious ways by certain natural ligands and related synthetic drugs. The state-of-the-art methods also often ignore the medium-to-low sequence specificity differences of closely related TFs, which in turn are crucial to understanding the vital differences in the biological functions among the NRs. This project’s first aim is to develop innovative computational approaches to elucidate the complex binding characteristics of NRs and to identify the vital differences in binding profiles of closely related NRs. The analysis will utilize recently collected experimental cognate site identification (CSI) data from high throughput sequencing of DNA-interactomes of all full-length functional human NRs in the context of whole cell extracts. We also propose to rigorously evaluate the impact of a wide-range of physiological small molecule ligands as well as prescribed therapeutics/drugs on NR-DNA interactomes. The computationally determined sequence preferences will be experimentally tested using biochemical, biophysical and cell biological assays. Thus we will integrate computation and experimental validation to decipher how NRs target the genome and manifest their biological roles. Moreover, the efforts will enable precision-medicine by defining the impact of current therapeutics in guiding NRs in the context of individual genomes.

项目总结/文摘